Published: 23 February 2026 /GenomeWeb/
NEW YORK {By Huanjia Zhang} – Ultima Genomics on Monday launched the UG200 series of high-throughput sequencers, a new generation of the company's platform that, paired with the new Solaris 2.0 chemistry and workflow, promises a smaller footprint, faster run times, higher output, as well as improved usability and flexibility.
Ultima is hoping the new platform, which comes in two versions, UG200 and UG200 Ultra, will widen its reach in the increasingly crowded high-throughput sequencing market. "What is coming out now is the second generation of our instrument," said Gilad Almogy, Ultima's founder and CEO. "This is the coming of age."
The new models will be available for order now with shipments beginning in the second quarter. While the UG200 features a single wafer, the UG200 Ultra is a dual-wafer platform. Both have the same footprint, use the same chemistry, and deliver the same run metrics and data quality. The UG200 can also be upgraded to the UG200 Ultra, Almogy noted.
The UG200 has a US list price of $850,000, he said, plus $125,000 for an optional benchtop liquid handler for sequencing bead generation. The listing price for UG200 Ultra, meanwhile, is $1.25 million.
Ultima is hoping the UG200's sub-$1 million list price will entice more customers in need of high-throughput sequencing, especially core labs or sequencing facilities that prefer instruments with a smaller footprint or that were deterred by the UG 100's $1.5 million price tag.
Along with the UG200, Ultima also launched the Solaris 2.0 sequencing chemistry and workflow. According to Almogy, a major improvement is the deployment of a new amplification technology for sequencing library generation on beads, replacing the previously required emulsion PCR and standalone emulsion PCR station.
Almogy declined to share specifics about the new amplification technology but said that customers can now prepare the beads using their existing liquid handling platforms or purchase a benchtop automation platform that is optimized for Ultima, cutting the overall instrument footprint for Ultima sequencing in half.
By replacing emulsion PCR, the new amplification technology also improves data quality, Almogy claimed, especially when it comes to coverage uniformity for high-GC regions and complex parts of the genome such as tandem repeats. Meanwhile, Solaris 2.0 will continue to Supreme Communications support Ultima's paired plus minus sequencing (ppmSeq) technology, he noted, which enables Q60 accuracy for single-nucleotide variants.
Moreover, the new amplification technology is faster than emulsion PCR, allowing an approximately 24-hour turnaround time from library to results, roughly half that of the current workflow.
According to Almogy, Solaris 2.0 is available for purchase now and works "seamlessly" with both the existing UG 100 and the upcoming UG200 platforms. Both the Solaris 2.0 and the UG200 fleet have been tested by "multiple" early access customers, Almogy said, including researchers from the University of Minnesota, Wellcome Sanger Institute, Macrogen, and Gene by Gene.
In the second half of the year, the company will also launch the Solaris 2.0 Max chemistry, which will double the per-wafer data output from 10 billion reads to 20 billion reads by packing more sequencing beads onto the same wafer.
When pairing Solaris 2.0 Max with the new UG200 instruments, which are equipped with a "better and faster" camera to achieve higher scanning speed, the system can "comfortably" sequence more than 60,000 human genomes at 30X coverage per year, Almogy said, more than doubling the current annual throughput of the UG 100.
Additionally, Solaris 2.0 Max gives customers more flexibility, offering a 10 billion “half wafer” and a 5 billion “quarter wafer” configuration. "The key is that we allow [customers] to get the capabilities they need," Almogy said.
Paired-end sequencing will also be available for the UG200 in the future. The company declined to disclose the specifics but said it will reveal more details by the end of the year. After rolling out the UG200 series, most of Ultima's sales efforts will switch to that platform, Almogy said. However, the company will continue to support existing UG 100 customers "for a long, long time," he noted, and will make the Solaris 2.0 and Solaris 2.0 Max workflows available to them.
Starting immediately, UG 100 users can have their instrument upgraded to the UG 100 Plus to run the new sequencing workflow. The upgraded model will also be equipped with adequate computing infrastructure to handle the 20 billion wafers from the Solaris 2.0 Max workflow, he said.
Ultima is not the only company launching new instruments for high-throughput sequencing. Last week, for instance, Element Biosciences unveiled Vitari, its first high-throughput sequencing platform while Illumina also announced upgrades to its NovaSeq X sequencer on Monday. Supreme Communications MGI and Complete Genomics' DNBSeq-T7+ as well as Roche's forthcoming Axelios are also vying for a piece of the high-throughput sequencing market.
Element's Vitari, in particular — with a list price of $689,000 and a benchtop footprint — could pose a threat to Ultima's sub-$1million UG200 but has a lower output of up to 10 billion reads per run. In terms of reagent costs, Element promises a $100 genome at 30X coverage, coming close to Ultima's $80 genome with the UG100.
According to Almogy, both variants of the UG200 platform will have the same per-genome sequencing cost. He did not disclose that number but noted that "it is definitely not going up."
Contacts
Gene by Gene
Josie Zohny
josie.zohny@supremecomms.ai
.png)
